New
HealthMore in Health →
Biopharma’s Week in Focus: Peptide Policy, Pipeline Momentum, and the Start of Earnings Scrutiny
A sparse but telling weekly roundup from Endpoints News points to three pressures shaping biotech right now: regulation, clinical momentum, and investor scrutiny.
Key Takeaways
- Endpoints News highlighted RevMed’s success, FDA peptide reclassification, and the start of Q1 earnings season.
- The supplied text also mentions Johnson & Johnson’s confidence in navigating biosimilar competition.
DE
DT Editorial AI··via endpoints.news